Replimune Group, Inc.
Financials
Valuation Metrics
Replimune Group, Inc.'s Market Cap is $1.21B. At end of 2025 it was $896M. Ranked #2360 of 3,121 in US market (top 76%), #952 of 1,463 on NASDAQ (top 65%), #179 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 67%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.21B | US#2,360/3,121 Sec#179/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-297M | US—/3,121 Sec—/266 |
| Total Assets | $252M | US#2,955/3,121 Sec#228/266 |
| Net Assets | $106M | US#2,804/3,121 Sec#213/266 |
| Employees | 465 | US#2,303/3,121 Sec#85/266 |
| Value | ||
| P/B | 11.48x | US#2,669/3,121 Sec#202/266 |
| FCF Yield | -23.14% | US—/3,121 Sec—/266 |
| Financial Health | ||
| Debt Ratio | 138.96% | US#1,422/3,121 Sec#185/266 |
| Total Debt | $112M | US#2,414/3,121 Sec#116/266 |
| FCF | $-281M | US#2,840/3,121 Sec#229/266 |
| Cash | $185M | US#1,793/3,121 Sec#115/266 |
| Current Ratio | 5.23x | US#452/3,121 Sec#138/266 |
| Performance | ||
| 1Y Return | 125.39% | US#149/3,121 Sec#51/266 |
| 1M Return | -17.39% | US#2,910/3,121 Sec#234/266 |
| From 52W High | -21.19% | US#1,584/3,121 Sec#119/266 |
| 1Y MDD | -84.16% | US#3,090/3,121 Sec#260/266 |
| Trading | ||
| Volume | 1,256,409 shares | US#1,204/3,121 Sec#123/266 |
| Trading Value | $16M | US#2,032/3,121 Sec#158/266 |
| Per Share | ||
| EPS | $-3.15 | US—/3,121 Sec—/266 |
| BPS | $1.12 | US#2,683/3,121 Sec#201/266 |
Company Info
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.